Literature DB >> 1892747

The effects of vasopressin infusion on hepatic haemodynamics in an experimental model of liver metastases.

D M Hemingway1, D Chang, T G Cooke, S A Jenkins.   

Abstract

Vasoactive drugs have a variety of effects upon splanchnic and hepatic haemodynamics which may alter tumour blood flow and potentiate the delivery of a chemotherapeutic drug to hepatic tumour. We have investigated the effects of vasopressin infusion on hepatic tumour blood flow in an experimental model of liver tumour. Hepatic tumour was induced by the intraportal inoculation of HSN sarcoma cells. Hepatic and splanchnic blood flow was determined using a dual reference microsphere technique before and after an intravenous infusion of vasopressin at a dose of 0.1 mU kg-1 min-1 for 10 min. There was a significant increase in systemic arterial blood pressure associated with a rise in portal venous inflow (P less than 0.01, Wilcoxen Signed rank Test) and a significant fall in hepatic arterial flow (P less than 0.05). The tumour: liver blood flow ratio was significantly increased by vasopressin infusion (P less than 0.02). Vasopressin infusion decreases hepatic arterial flow and increases tumour blood flow which may potentiate the delivery of a regionally delivered chemotherapeutic drug to hepatic tumour.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1892747      PMCID: PMC1977507          DOI: 10.1038/bjc.1991.278

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  Simultaneous measurement of cardiac output and its distribution with microspheres in the rat.

Authors:  D G McDevitt; A S Nies
Journal:  Cardiovasc Res       Date:  1976-07       Impact factor: 10.787

2.  Survival of patients treated with systemic fluorouracil for hepatic metastases.

Authors:  A H Rapoport; R L Burleson
Journal:  Surg Gynecol Obstet       Date:  1970-05

3.  Influence of vasoactive drugs and ischaemia on intra-tumour blood flow distribution.

Authors:  J Mattson; L Appelgren; L Karlsson; H I Peterson
Journal:  Eur J Cancer       Date:  1978-07       Impact factor: 9.162

4.  Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer.

Authors:  Y Sasaki; S Imaoka; Y Hasegawa; S Nakano; O Ishikawa; H Ohigashi; K Taniguchi; H Koyama; T Iwanaga; T Terasawa
Journal:  Cancer       Date:  1985-01-15       Impact factor: 6.860

5.  Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.

Authors:  J A Goldberg; D J Kerr; N Wilmott; J H McKillop; C S McArdle
Journal:  Br J Surg       Date:  1990-11       Impact factor: 6.939

6.  The effects of vasopressin on hepatic haemodynamics in the cirrhotic and non-cirrhotic rat.

Authors:  S A Jenkins; D W Day; B Mooney; P Devitt; J N Baxter; I Taylor; R Shields
Journal:  Langenbecks Arch Chir       Date:  1985

7.  Effect of vasopressin on liver blood flow in the hypophysectomised rat.

Authors:  S A Jenkins; B Mooney; I Taylor; R Shields
Journal:  Digestion       Date:  1984       Impact factor: 3.216

8.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

  8 in total
  3 in total

1.  Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Authors:  Jeff S Isenberg; Fuminori Hyodo; Lisa A Ridnour; Caitlin S Shannon; David A Wink; Murali C Krishna; David D Roberts
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

2.  The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases.

Authors:  D M Hemingway; S A Jenkins; T G Cooke
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

3.  Nitric oxide inhibition sustains vasopressin-induced vasoconstriction.

Authors:  M J Dworkin; P Carnochan; T G Allen-Mersh
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.